These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34032996)

  • 1. A latent variable approach to account for correlated inputs in global sensitivity analysis.
    Melillo N; Darwich AS
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):671-686. PubMed ID: 34032996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models.
    Scherholz ML; Forder J; Androulakis IP
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):309-327. PubMed ID: 29423863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of Sobol's Sensitivity Indices under Generalized Linear Models.
    Lu R; Wang D; Wang M; Rempala GA
    Commun Stat Theory Methods; 2018; 47(21):5163-5195. PubMed ID: 30237653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics.
    Melillo N; Darwich AS; Magni P; Rostami-Hodjegan A
    J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):137-154. PubMed ID: 30905037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling.
    Hsieh NH; Reisfeld B; Bois FY; Chiu WA
    Front Pharmacol; 2018; 9():588. PubMed ID: 29937730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds.
    Melillo N; Grandoni S; Cesari N; Brogin G; Puccini P; Magni P
    AAPS J; 2020 Aug; 22(5):116. PubMed ID: 32862303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.
    Melillo N; Aarons L; Magni P; Darwich AS
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development.
    Johnson TN; Small BG; Berglund EG; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):967-972. PubMed ID: 34288581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models.
    Liu D; Li L; Rostami-Hodjegan A; Bois FY; Jamei M
    AAPS J; 2020 Jul; 22(5):93. PubMed ID: 32681207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of supervised principal component analysis for global sensitivity analysis of models with correlated inputs.
    Sharbaf MAMJ; Abedini MJ
    Stoch Environ Res Risk Assess; 2022; 36(9):2789-2818. PubMed ID: 35095342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Methodology for Global Sensitivity Analysis of Activated Sludge Models: Case Study with Activated Sludge Model No. 3 (ASM3).
    Fortela DLB; Farmer K; Zappi A; Sharp WW; Revellame E; Gang D; Zappi M
    Water Environ Res; 2019 Sep; 91(9):865-876. PubMed ID: 31004529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.
    Guo Y; Chu X; Parrott NJ; Brouwer KLR; Hsu V; Nagar S; Matsson P; Sharma P; Snoeys J; Sugiyama Y; Tatosian D; Unadkat JD; Huang SM; Galetin A;
    Clin Pharmacol Ther; 2018 Nov; 104(5):865-889. PubMed ID: 30059145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
    Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
    Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.
    Gaohua L; Miao X; Dou L
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134
    [No Abstract]   [Full Text] [Related]  

  • 15. LCA of emerging technologies: addressing high uncertainty on inputs' variability when performing global sensitivity analysis.
    Lacirignola M; Blanc P; Girard R; Pérez-López P; Blanc I
    Sci Total Environ; 2017 Feb; 578():268-280. PubMed ID: 27836349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling.
    Rowland Yeo K; Gil Berglund E
    Clin Pharmacol Ther; 2021 Nov; 110(5):1168-1171. PubMed ID: 33934342
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation and recommendation of sensitivity analysis methods for application to Stochastic Human Exposure and Dose Simulation models.
    Mokhtari A; Christopher Frey H; Zheng J
    J Expo Sci Environ Epidemiol; 2006 Nov; 16(6):491-506. PubMed ID: 16519411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
    Johnson TN; Ke AB
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S83-S93. PubMed ID: 34185901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.